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Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is an adult onset
neurodegenerative disorder characterised by the degeneration of cortical and spinal cord motor
neurons, resulting in progressive muscular weakness and death. Increasing evidence supports
mitochondrial dysfunction and oxidative DNA damage in ALS motor neurons. Several DNA repair
enzymes are activated following DNA damage to restore genome integrity, and impairments in
DNA repair capabilities could contribute to motor neuron degeneration. After a brief description
of the evidence of DNA damage in ALS, this paper focuses on the available data on DNA repair
activity in ALS neuronal tissue and disease animal models. Moreover, biochemical and genetic
data on DNA repair in ALS are discussed in light of similar ﬁndings in other neurodegenerative
diseases.
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1. INTRODUCTION
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is an adult onset
neurodegenerative disorder characterised by the degeneration of motor neurons of the motor cortex,
brainstem, and spinal cord, resulting in progressive weakness and death. The course of the disease is
inexorably progressive, with almost 50% of the patients dying within 3 years of onset, generally due to
respiratory failure. The typical age at onset is between 50 and 60 years, and the incidence of the disease is
similar worldwide ranging from 1 to 3 new cases per 100.000 individuals every year. ALS is predominantly
a sporadic disorder (sALS), and only 5 to 10% of the cases have a familial origin (fALS). Studies in families
led to the identiﬁcation of several genes and potential loci responsible for familial ALS cases, whereas the
development of the sporadic forms is likely the result of complex gene-environment interactions not yet
completely clariﬁed [1–3].
The gene encoding for the cytosolic copper-zinc superoxide dismutase protein (SOD1), on
chromosome 21q21, was the ﬁrst ALS identiﬁed gene (SOD1), accounting for autosomal dominant forms.
Superoxide dismutases are scavenger enzymes against free radicals mainly produced by mitochondrial
respiration, and SOD1 mutations account for approximately 20% of the familial forms. Other common
pathogenic ALS mutations have been identiﬁed in the 43-KDa TAR DNA-binding protein (TARDBP)a n d
fused in sarcoma (FUS) genes, accounting for approximately 4-5% of fALS cases each. Less common
genetic mutations causing fALS include those in alsin (ALS2), senataxin (SETX), spatacsin (SPG11),
vesicle-associated membrane protein/synaptobrevin-associated membrane protein B (VAPB), angiogenin
(ANG), phosphoinositide phosphatase (FIG4), and optineurin (OPTN) genes, overall accounting for less
than 5% of fALS cases [2, 3]. Further, mutations in the dynactin gene (DCTN1) on chromosome 2p13
have been observed in a family with a slowly progressive motor neuron disease, with some clinical
features overlapping ALS [4]. Variants in other genes have been suggested to be associated with fALS
or found in families with atypical ALS phenotypes, but results are still inconclusive leaving more than
50% of the genetics of fALS yet to be identiﬁed [2, 3]. Common polymorphisms in several genes
have been hypothesized to be associated with increased risk to develop sporadic ALS forms, including
angiogenesis genes (ANG and VEGF), variant sequences of neuroﬁlament proteins (NEFL, NEFM, and
NEFH), DNA repair genes (APEX1 and OGG1), paraoxonase genes (PON1, PON2,a n dPON3), survival
motor neuron genes (SMN1 and SMN2), and the haemochromatosis gene (HFE)[ 5]. The ALSGene
database (http://www.alsgene.org/) is a recently available public database containing data on ALS genetic
association studies, including genome-wide association studies (GWAS). The database is continuously
updated, and meta-analyses are performed for those polymorphisms which have been investigated in
at least four independent studies. Accessed on June 2011, the database contained information on 284
polymorphisms in 90 genes, and 21 meta-analyses were available. The available meta-analyses revealed
signiﬁcant associations between four gene polymorphisms (APEX1 rs1130409, GWA 9p21.2 rs2814707,
HFE rs1799945,and UNC13A rs12608932)andALS risk. Moreover, two additional polymorphisms (DPP6
rs10260404 and ATXN2-polyQ-3bpSTR) resulted associated with ALS risk in two independent large-scale
association studies each (http://www.alsgene.org/). Concerning ANG, VEGF, and PON genes, recently
published meta-analyses [6, 7] and updated meta-analyses (http://www.alsgene.org/) failed to replicate
association with disease risk, with the exception of the VEGF-2578AA genotype in males [7].
There is evidence that sALS is more common in men than in women and that gender inﬂuences the
clinical features of the disease. Generally, the male/female ratio for incidence is greater at younger ages
and tends to disappear with increasing age. Moreover, sALS males have a greater likelihood of onset in the
spinal regions, and females in the bulbar region [8]. Therefore, it is not surprising that also genetic variants
might have a different role in disease risk after stratiﬁcation by gender.
Concerning environmental factors, the ﬁrst evidence of an environmental contribution to ALS came
from the observed endemic occurrence of ALS with parkinsonism and progressive dementia in regions of
Western Paciﬁc that could not be fully explained by genetic factors and was related to the consumption of
food made with seeds of the cycad plants [9]. Several other environmental factors have been extensively
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studied in recent years. The most consistent associations are exposure to pesticides, heavy metals including
lead and mercury, an excessive physical activity such as playing professional soccer, head injuries, cigarette
smoking, and occupational exposure to electromagnetic ﬁelds, even if, to date, no deﬁnitive causal link has
been consistently established [10–12].
Studies with ALS animal models indicate that the overexpression of mutant SOD1 in mice leads
to symptoms similar to those observed in humans [13, 14], suggesting that a toxic gain of function for
the mutant gene might be responsible for the disease. Another study indicates that the toxicity of mutant
SOD1 might arise from an initial misfolding (gain of function) reducing nuclear protection against oxidative
DNA damage compared with the wild-type enzyme [15]. Moreover, neurons obtained from Als2 knock-
out mice are more vulnerable to oxidative damage compared to primary cultured neurons derived from
controls, suggesting that the loss of the gene predisposes to oxidative damage [16]. More recently, it was
observed that the transfection of mutant TAR DNA-binding protein-43 induces mitochondrial dysfunction
and oxidative damage in motor neuron-like cells [17]. Moreover, senataxin is a member of the superfamily
I DNA/RNA helicases, likely involved in oxidative DNA damage response [18]. Several authors report
increased oxidative damage in cortical neurons, spinal cords, and other tissues of each of sALS and fALS
patients, and a compromised DNA repair activity in ALS has been largely suggested [19–21]. After a brief
description of oxidative DNA damage in either ALS tissues or disease animal models, this paper describes
the current knowledge on DNA repair activity in ALS.
2. DNA REPAIR: THE DNA BASE EXCISION REPAIR PATHWAY
It is estimated that every day each single cell of the human body is subjected to an average of approximately
one million DNA lesions, including apurinic/apyrimidinic (AP) sites (abasic sites), DNA adducts, single-
strand breaks (SSBs), double-strand breaks (DSBs), insertion/deletion mismatches, and DNA-protein
crosslinks, all arising as a consequence of either endogenous or exogenous factors. Several DNA repair
mechanisms are therefore operative in human cells to counteract the daily amount of DNA damage,
including the DNA base excision repair (BER) pathway that primarily removes DNA bases modiﬁed by
oxidation, alkylation, and deamination, the nucleotide excision repair pathway (NER) that operates on
UV photoproducts, DNA crosslinks, and DNA bulky lesions, mismatch repair (MMR) that corrects base
mismatches and small insertions or deletions during replication, and DSBs repair mechanisms such as
homologous recombination (HR) and nonhomologous end joining (NHEJ) that repair DNA DSBs such as
those caused by ionizing radiations [22, 23].
The DNA base excision repair (BER) pathway deserves a detailed description in order to understand
the following sections of this paper since it is believed to be the major pathway for repairing DNA base
modiﬁcations caused by oxidation and has been largely investigated in ALS tissues and animal models
(Table 1).
The ﬁrst step in BER is the recognition of a damaged base by an appropriate DNA glycosylase
that catalyzes the cleavage of the N-glycosylic bond between the damaged base and the sugar moiety;
after the cleavage, the damaged base is released resulting in the formation of an abasic site which is then
cleaved by an AP lyase activity (an activity present in some DNA glycosylases) or by the major mammalian
apurinic/apyrimidinic endonuclease (APEX1). Repair can then proceed through short- or long-patch BER.
In short-patch BER, which is the most common subpathway, a single nucleotide is incorporated into the
gap by DNA polymerase β (Pol β), the same polymerase also removes the 5 -sugar phosphate, and the
DNA ligase III/X-ray repair cross-complementing group 1 (XRCC1) complex seals the DNA ends. Thus,
Pol β carries out two distinct reactions in BER; it uses its DNA polymerase activity to ﬁll in the one-
nucleotide gap, and it also uses its 5 -deoxyribophosphatase activity to cleave the 5  phosphate to allow
for efﬁcient ligation. However, if the 5 -deoxyribophosphate (5 dRP) is reduced or oxidised, and therefore
resistant to the action of Pol β, then an additional synthesis of DNA is required to displace the modiﬁed
5 -sugar phosphate as part of aﬂap, which is then removed byﬂap endonuclease(FEN1). Therefore, in long-
patch BER, several nucleotides (two to seven-eight) are incorporated, followed by cleavage of the resulting
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TABLE 1: Levels and activity of DNA repair proteins in motor neurons of ALS patients and disease animal
models.
Protein Function Activity in ALS References
↓ in ALS motor cortex [20]
Apurinic/apyrimidinic
endonuclease 1
(APEX1)
DNA endonuclease (BER pathway)
↑ in ALS motor cortex and spinal cord
motor neurons
[24]
↓ in spinal cord motor neurons of
SOD1 transgenic mice
[25]
↓ mitochondrial activity in ALS motor
neurons
[21]
8-Oxoguanine DNA
glycosylase (OGG1)
DNA glycosylase that speciﬁcally
removes 8-oxoguanine from the
DNA (BER pathway)
↑ nuclear levels in spinal cord motor
neurons of SOD1 transgenic mice
[26]
= unchanged mitochondrial levels in
spinal cord motor neurons of SOD1
transgenic mice
[26]
DNA polymerase γ
(Pol γ)
Mitochondrial DNA polymerase
(BER pathway)
↓ in spinal cord motor neurons of
SOD1 transgenic mice
[26]
↑ expression in astrocytes of the spinal
cord of ALS patients
[27]
Poly-ADP-ribose
polymerase-1
(PARP1)
Recognition of DNA damage (DNA
repair)
↓ expression in motor neurons of the
spinal cord of ALS patients
[28]
↑ expression in motor cortex, parietal
cortex, and cerebellum of ALS patients
[28]
DNA excision repair
protein ERCC-1
Repair protein primarily involved in
NER pathway
Errc1 knock-out mice showed
age-related motor neuron degeneration
[29]
5  ﬂap structure and ligation. It has been suggested that after Pol β adds the ﬁrst nucleotide into the gap, it
is substituted by Pol δ/ε which continues long-patch BER. DNA ligase I completes the long-patch pathway.
Several other proteins include the proliferating cell nuclear antigen (PCNA), the RPA protein, and FEN-1
participate in long-patch BER [30, 31]. A diagram illustrating the BER pathway is shown in Figure 1.
Several different DNA glycosylases, each speciﬁc for certain lesions, operate in human cells.
However, individual glycosylases may recognize more than one type of damage, and each speciﬁcl e s i o n
may be recognized by more than one type of glycosylase, allowing some degrees of redundancy in
the process. Moreover, monofunctional glycosylases such as the uracil DNA glycosylase (UNG) have
only glycosylase activity and require APEX1 for the incision of the resulting sugar residue. In contrast,
bifunctional glycosylases such as oxoguanine DNA glycosylase (OGG1) have both glycosylase and AP
lyase activity. The diagram illustrated in Figure 1 should be considered only as indicative of the process,
since there is indication of interaction and cooperation between the enzymes at successive steps in BER.
For example, XRCC1 acts as a scaffold protein in short-patch BER, regulating and coordinating the whole
process. XRCC1 recruits DNA Pol β and DNA ligase III required for ﬁlling and sealing the damaged
strand. Moreover, it also interacts with DNA glycosylases and APEX1, mediating their exchange at the
damaged site. There is a speciﬁc interaction between APEX1 and Pol β that assembles the polymerase onto
the AP site in DNA. XRCC1 also interacts with poly-ADP-ribose polymerase-1 (PARP-1), which is one
of the cellular sensors of DNA SSBs and DSBs. Long-patch BER requires the nuclear protein PCNA that
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FIGURE 1: Diagram illustrating the DNA base excision repair (BER) pathway. In this pathway, a DNA
glycosylase catalyzes the removal of a damaged base, creating an abasic (AP) site. The APEX1
endonuclease catalyzes the incision of the DNA backbone leaving behind a 5 -deoxyribose phosphate
(5 dRP, indicated with a black circle). In short-patch BER, polymerase β (Pol β) displaces the AP site and
polymerizes DNA to ﬁll in the gap. Pol β then catalyzes the removal of the displaced AP site, and the
ligase III/XRCC1 complex seals the ends. If the 5 dRP is refractory to the action of Pol β, then an additional
synthesis of DNA (long-patch BER) is required to displace the modiﬁed 5 -sugar phosphate as part of a ﬂap
(in grey), which is then removed by ﬂap endonuclease (FEN1). Pol β adds the ﬁrst nucleotide into the gap
and is substituted by polymerase δ/ε which continues long-patch BER. DNA ligase I (LIG1) completes the
long-patch pathway.
promotes this pathway via its ability to interact with and coordinate the activity of a DNA polymerase and
FEN1. Moreover, the decision to proceed via the long-patch or short-patch BER is still poorly understood
and might depend on the availability of ATP and/or by the state of the 5 -dRP intermediate [30].
BER takes places either in nuclei and mitochondria, and mitochondria have independent BER
machinery encoded by nuclear genes. Indeed, several BER enzymes have been identiﬁed which have
both nuclear and mitochondrial forms. For example, among DNA glycosylases, nuclear and mitochondrial
adenine-DNA-glycosylases are generated by alternative spliced forms of the MYH gene. Similarly nuclear
and mitochondrial uracil DNA glycosylases are encoded by alternative splicing and transcription of the
UNG gene, and two isoforms of the human oxoguanine DNA glycosylase operate in human cells, the alpha
and the beta forms, arising as alternative splice products from the OGG1 gene. The beta form operates in
mitochondria, while the alpha form operates in the nucleus as well as in mitochondria; however, it seems
that the alpha form is responsible for the base excision activity also in mitochondria, whilst the beta form
lacks DNA glycosylase activity, and its function remains unclear. The gaps generated by the action of AP
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endonucleases/lyases are ﬁlled in by the DNA polymerase γ (Pol γ) in the mitochondria, and ligation is
mediated by ligase III. There is also some recent evidence of long-patch BER in mitochondria [32].
3. OXIDATIVE DNA DAMAGE IN AMYOTROPHIC LATERAL SCLEROSIS
A wide variety of reactive oxygen species (ROS) are produced in biological systems during the course of the
normal metabolism, and they have several important physiological functions. However, the accumulation of
ROS beyond the needs of the cell can potentially damage several biomolecules, including lipids, proteins,
and nucleic acids. Mammalian cells have an intricate network of defence mechanisms, such as superoxide
dismutases, to neutralize an excessive accumulation of ROS and, under physiological conditions, are able
to cope with the ﬂux of ROS. Oxidative stress describes a condition in which cellular antioxidant defences
are insufﬁcient to keep the levels of ROS below a toxic threshold. Some tissues, including neuronal and
muscular tissues, are much more vulnerable to oxidative stress because of their elevated consumption of
oxygen required to produce energy and the consequent generation of large amounts of ROS. Evidence
of oxidative damage to lipids, proteins, and nucleic acids has been largely detected in spinal cords,
cerebrospinal ﬂuid (CSF), and other tissues of both sALS and fALS patients [33].
The type of DNA damage that most likely occurs in neuronal cells is oxidative damage, which
is primarily removed by the DNA base excision repair (BER) pathway [34]. Oxidative DNA damage
accumulates in the DNA of the neurons over time, especially in mitochondrial DNA (mtDNA), and is
supposed to play a critical role in the pathogenesis of several neurodegenerative diseases, including ALS
[19, 35, 36]. The mtDNA is believed to be particularly sensitive to oxidative damage due to its proximity
to the inner mitochondrial membrane, where oxidants are formed. Several of the mtDNA genes encode for
subunits of the mitochondrial respiratory chain; thus, oxidative mtDNA damage, if not correctly repaired,
could result in mutations and deletions disrupting the function of genes involved in the production of ATP
and leading to mitochondrial dysfunctions, increased production of ROS, and cellular death. Therefore, a
decline in one or more BER enzymes may result in the accumulation of nDNA and mtDNA mutations
ultimately leading to the production of altered proteins and possible neurodegeneration [31].
In case of oxidative DNA damage, one of the major alterations in the DNA is the formation of
8-hydroxy-2 -deoxyguanosine (8-OHdG), and increased levels of 8-OHdG have been identiﬁed in the
neuronal DNA of the motor cortex of sALS patients, and in both sALS and fALS spinal cords [19]. The
analysis of plasma, urine, and CSF of ALS patients revealed increased levels of 8-OHdG. Moreover, plasma
and urine 8-OHdG levels increased signiﬁcantly with time in the ALS group, and the rate of increase in
urine 8-OHdG levels with time was signiﬁcantly correlated with disease severity [35]. Another study aimed
at evaluating oxidative damage in blood and CSF of each of sALS and fALS patients showed that blood
concentrations of hydroxyl radicals and CSF values of 8-OHdG and ascorbate free radical were higher in
both sALS and fALS patients compared to controls [37]. Increased oxidative damage to the nuclear DNA,
measured as the content of 8-OHdG, has been also observed in the G93A-SOD1 transgenic mouse model of
fALS [36]. The analysis of 8-OHdG levels in the spinal cord of transgenic mice harbouring a mutant SOD1
gene showed oxidative damage to mtDNA in spinal motor neurons from very early stage of the disease [38].
OthersobservedthatinG93A-SOD1mutantmice,motorneurondegenerationischaracterizedbysomaland
mitochondrial swelling and formation of DNA single-strand breaks prior to double-strand breaks occurring
in nuclear and mitochondrial DNA. Single-strand breaks of nuclear DNA and mtDNA were evident in
motor neurons of 6-week old mice, and double-strand breaks appeared by 9 weeks of age and progressively
increased thereafter [39]. It was also demonstrated that, in sporadic ALS, there is a selective decrease in
the activity of the mtDNA-encoded enzyme cytochrome c oxidase in human spinal cord motor neurons, and
authors proposed that this could well be caused by oxidative damage to mtDNA leading to the accumulation
of mtDNA mutations [40]. Murata et al. [41] measured the concentrations of the reduced and oxidized forms
of coenzyme Q10 (CoQ10) and 8-OHdG in the CSF of sALS patients and age-matched healthy controls,
observing increased levels of both oxidized CoQ10 and 8-OHdG in the CSF of sALS patients more than in
the CSF of controls. Moreover, the percentage of oxidized CoQ10 was correlated with the concentrations of
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8-OHdG in the CSF of sALS patients, suggesting that both mitochondrial oxidative damage and oxidative
DNA damage play important roles in the pathogenesis of sALS [41]. Signiﬁcantly higher levels of oxidative
DNA damage and DNA strand breaks, increased p53 activity, and a greater percentage of apoptotic cells
were observed in SH-SY5Y neuroblastoma cells overexpressing the mutant G93A-SOD1 protein when
compared to cells overexpressing wild-type SOD1 and untransfected cells [42]. Collectively, the available
datasuggestincreasednuclearandmitochondrialDNAdamageinALS,likelycontributingtomitochondrial
dysfunction and death of motor neurons.
4. DNA REPAIR IN AMYOTROPHIC LATERAL SCLEROSIS
Almost 30 years ago, Bradley and Krasin advanced the hypothesis that the primary abnormality in ALS is
the accumulation of abnormal DNA, which is unable to undertake normal transcription in motor neurons,
and suggested that this abnormal DNA may arise from a deﬁciency of an isozyme of one of the DNA repair
enzymes [43]. A few studies performed over 20 years ago revealed that skin ﬁbroblasts obtained from sALS
patients were relatively deﬁcient in the repair of alkylation damage, possibly of apurinic/apyrimidinic sites
[44, 45]. This has driven researchers to investigate the activity of the apurinic/apyrimidinic enzyme in ALS
tissues, and the frontal cortical levels and the activity of APEX1 (alternatively called APE1 or APE/Ref-1)
were determined in 11 sALS patients and 6 age-matched controls, resulting signiﬁcantly reduced in sALS
patients than in controls [20]. Others observed an increased APEX1 activity in ALS motor neurons and
suggested that DNA damage could be an upstream mechanism for motor neuron degeneration in ALS
and that mechanisms for DNA repair are activated in this disease [24]. APEX1 expression was also
examined in the spinal cord of transgenic mice expressing an ALS-linked mutant SOD1. Immunoblotting
and immunocytochemical analyses showed that most spinal motor neurons lost the immunoreactivity for
APEX1 in the early presymptomatic stage that preceded signiﬁcant loss of the neurons, suggesting that an
early impairment of DNA repair in the spinal motor neurons may account for the mutant SOD1-mediated
motor neuronal death in this model [25].
OGG1 is the DNA glycosylase that speciﬁcally removes oxidized guanine from DNA. Increased
levels of 8-OHdG and an impaired mitochondrial OGG1 activity were observed in the spinal motor neurons
of sALS individuals compared with control subjects, indicating that oxidative DNA damage accumulates in
the mtDNA and that OGG1 does not repair it efﬁciently [21]. Another study showed that nuclear ogg1 levels
were increased, while mitochondrial ogg1 remained unchanged, and mitochondrial DNA polymerase γ was
downregulated in spinal cord motor neurons of SOD1 transgenic mice [26]. More recently, an age-related
motor neuron degeneration was observed in DNA repair-deﬁcient Ercc1 mice, that is, mice that are impaired
in several DNA repair systems, including nucleotide excision repair (NER), interstrand crosslink repair, and
double-strand break repair, supporting the notion that accumulation of DNA damage and genotoxic stress
may contribute to neuronal aging and motor neuron vulnerability in human neuromuscular disorders [29].
PARP-1 is a zinc-ﬁnger DNA-binding protein that is activated by single-strand breaks or double-
strand breaks in DNA. The primary function of PARP-1 is in DNA repair processes through the detection of
DNA damage and the prevention of chromatid exchanges. PARP-1 poly-ADP-ribosylates several proteins
involved in DNA repair including histones, thus inducing local relaxation of the chromatin structure and
facilitating the access of repair proteins to damaged DNA. However, PARP-1 activation can also result
in cell death. Indeed, cells with extensive DNA damage have a widespread PARP-1 activation with a
subsequent depletion of its substrate NAD+, and then ATP, leading to energy failure and cell death.
Using immunohistochemical analyses of postmortem tissue, Kim et al. [27] demonstrated that PARP-1
expression is increased in astrocytes but decreased in motor neurons in the spinal cord of sporadic ALS
patients. The same group observed that in ALS brain, PARP-1 expression was increased in the motor
cortex, parietal cortex, and cerebellum. PARP-1 immunostaining in the motor cortex was increased in
ALS neurons and subcortical glia and macrophages. Moreover, there was widespread increased PARP-1
expression in neurons in the parietal cortex and cerebellum, regions that are typically clinically unaffected
in ALS, suggesting widespread oxidative stress [28]. A summary of DNA repair activity in ALS is shown
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in Table 1. Collectively, the available data suggest that DNA repair mechanisms are activated following
oxidative DNA damage in ALS tissues, and that impairments in DNA repair activities might contribute to
the accumulation of DNA damage critical for motor neuron survival.
The results of studies attempting to evaluate the association between variants and polymorphisms of
BER genes and sALS risk have been conﬂicting and inconsistent. Common BER polymorphisms, including
APEX1 Asp148Glu (rs1130409), OGG1 Ser326Cys (rs1052133), XRCC1 Arg194Trp (rs1799782), XRCC1
Arg280His (rs25489), and XRCC1 Arg399Gln (rs25487), have been investigated as candidate sALS risk
factors [46–53]. However, despite some positive associations in initial studies [47, 49, 51, 52], subsequent
research has failed to replicate those ﬁndings [48, 50, 53]. Additionally, all the studies were largely limited
by the sample size of case-control groups [46–53]. Also a reanalysis of GWAS data failed to conﬁrm
association between XRCC1 polymorphisms and sALS risk [53].
5. DISCUSSION AND CONCLUSIONS
The present paper describes the currently available literature concerning DNA repair in ALS. Overall,
mitochondrial dysfunction and oxidative DNA damage have been largely detected in motor neurons of
either ALS patients or disease animal models [19, 35–41], and a widespread PARP-1 activation was
observed in several ALS brain regions [28], consistent with an increase in DNA damage. The activity of
APEX1 resulted increased in ALS spinal cord motor neurons [24] and decreased in ALS cortical neurons
or in spinal cord motor neurons of SOD1 transgenic mice [20, 25]. The activity of other BER enzymes
resulted increased, unchanged, or reduced, depending on the enzyme or the model analysed (Table 1). These
apparently contradictory ﬁndings have been observed also in other major neurodegenerative diseases such
as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Overall, increased oxidative DNA damage, a
widespread PARP-1 activation, and an increased expression of BER enzymes were observed in neurons
of AD, PD, and ALS individuals suggesting that DNA repair mechanisms could be activated following
oxidative DNA attack in early stages of the neurodegenerative process (for a review, see [23]). However,
several investigators reported reduced/impaired BER activity in AD-, PD-, or ALS-affected tissues [23],
suggesting that following a persistent condition of oxidative stress in neurons, DNA repair proteins,
activated to counteract the oxidative insult, could be themselves the subject of ROS attack resulting in
protein modiﬁcation and degradation, and ultimately leading to a reduced DNA repair activity. For example,
there is some indication that OGG1 activity might be impaired by posttranslational oxidative modiﬁcations
and degradation in AD, suggesting that increased oxidative stress in AD brain neurons could cause BER
impairments [54, 55].
Another interesting question is whether or not inherited DNA repair impairments, such as
those caused by inherited gene variants, could contribute to the neurodegenerative process. Hereditary
spinocerebellar ataxias deﬁcient in DNA damage responses represent the most robust set of data linking
mutations in DNA repair genes to neurodegeneration (reviewed in [56]). Spinocerebellar ataxia with
axonal neuropathy 1 (SCAN1) is caused by autosomal recessive mutations in the gene encoding tyrosyl-
DNA phosphodiesterase 1 (TDP1), a protein required for the repair of DNA single-strand breaks that
arise independent of DNA replication from abortive topoisomerase 1 activity or oxidative stress. Ataxia-
telangiectasia (AT), ataxia-telangiectasia-like disorder (ATLD), ataxia oculomotor apraxia type 1 (AOA1),
and ataxia oculomotor apraxia type 2A (AOA2) are a subgroup of the autosomal recessive spinocerebellar
ataxias characterized by cerebellar atrophy and oculomotor apraxia. The progressive neurodegeneration
described in AT and ATLD is due to mutations in genes encoding for ATM and Mre11, respectively.
ATM recognizes and signals DNA double-strand breaks to the cell cycle checkpoints and the DNA repair
machinery. The Mre11 DNA repair complex, composed of Rad50, Mre11, and Nbs1 proteins, is involved in
DNA damage recognition, DNA repair, and initiating cell cycle checkpoints. ATM and the Mre11 complex
combine to recognize and signal DNA double-strand breaks. AOA1 is caused by mutations in the gene
encoding aprataxin (APTX), a nuclear protein that interacts with several DNA repair proteins, including
XRCC1, DNA polymerase β, DNA ligase III, PARP-1, and p53. It functions in the end processing of DNA
1686TheScientiﬁcWorldJOURNAL (2011) 11, 1679–1691
single-strand breaks removing 3 -phosphate, 5 -phosphate, and 3 -phosphoglycolate ends. AOA2 is caused
by autosomal recessive mutations in the gene encoding senataxin (SETX)[ 56] .S E T Xi sam e m b e ro ft h e
superfamily I DNA/RNA helicases, likely involved in oxidative DNA damage response, and, as discussed
in the introduction section of this paper, SETX mutations have been also linked to familial ALS [1, 18].
Parkin is an E3 ubiquitin ligase that acts on a variety of substrates, resulting in polyubiquitination
and degradation by the proteasome or monoubiquitination and regulation of biological activity. Mutation
of parkin is one of the most prevalent causes of autosomal recessive familial PD, and a recent study has
shown that parkin is essential for optimal repair of DNA damage. Particularly, DNA damage induces
nuclear translocation of parkin leading to interactions with nuclear proteins involved in DNA repair [57].
Moreover, parkin protects mitochondrial genome integrity and supports mtDNA repair [58]. Missense
mutations in the gene encoding mitochondrial DNA polymerase γ (POLG1) cosegregate with a phenotype
thatincludesprogressiveexternalophthalmoplegiaandparkinsonismandhavebeenreportedincasestudies,
in which parkinsonism was part of the clinical symptoms [59, 60]. In addition, a POLG1 polymorphism (a
polymorphic polyglutamine tract in the N-terminal region of the protein) has been associated with risk of
sporadic idiopathic PD [61].
To date, there is no clear evidence linking mutations in DNA repair genes to AD. Novel OGG1
mutations leading to a serious impairment in protein activity have been observed in nuclear DNA from
postmortem brain specimens of 4 AD subjects, but no causal link with the disease has been yet proven [62].
Concerning ALS, inconsistent and/or contradictory ﬁndings have been observed when attempting to
evaluate common BER gene polymorphisms as candidate sALS risk factors [46–53].
Similarly, common BER gene polymorphisms, namely, OGG1 Ser326Cys, APEX1 Asp148Glu,
XRCC1 Arg194Trp, XRCC1 Arg280His, and XRCC1 Arg399Gln, are not signiﬁcantly associated with
increased AD risk [63–66], and the OGG1 Ser326Cys polymorphism does not affect PD risk or age at onset
[67]. There is however evidence that PARP-1 haplotypes could contribute to both AD and PD risk [68–
70]. Interestingly, there is also evidence of BER involvement in Huntington’s disease (HD), a progressive
neurodegenerative disorder resulting in cognitive impairment, choreiform movements, and death which
usually occurs 15–20 years after the onset of the symptoms. HD is an autosomal dominant disorder caused
by a CAG repeat expansion within exon 1 of the gene encoding for huntingtin (IT15). Disease age at onset
is inversely correlated with the number of CAG repeats, and the OGG1 protein has been involved in somatic
expansion of the CAG repeat tract in HD cells, occurring during the repair of oxidative DNA damage in the
CAG repeat tract and likely contributing to disease age at onset [71].
The recent observation of age-related motor neuron degeneration in DNA repair-deﬁcient Ercc1
mice [29] supports the notion that the impairment of additional DNA repair mechanisms, such as the
nucleotide excision repair pathway, might contribute to motor neuron vulnerability. NER involves at least
20–30 proteins or complexes of proteins and is required for the removal of a wide variety of forms
of DNA damage, including UV-induced photoproducts, DNA crosslinks, and other bulky DNA lesions.
Xeroderma pigmentosum (XP), Cockayne’s syndrome (CS), and trichothiodystrophy (TTD) represent a
clinically heterogeneous group of progeroid syndromes characterized by defects in NER proteins. A subset
of these patients exhibit neurological dysfunction and neurodegeneration, and several studies performed
in mice, as well as in cell cultures, suggest that neurodegeneration in XP and CS patients might arise as
a consequence of impaired repair of DNA lesions caused by mutations of NER genes (reviewed in [23]).
More recently, it has been suggested that polymorphisms of NER genes might contribute to the risk of
multiple sclerosis, an inﬂammatory demyelinating disease of the central nervous system characterized by a
signiﬁcant neurodegenerative component [72].
In summary, increasing evidence supports a role for DNA repair mechanisms in neurodegenerative
diseases, and an impaired DNA repair activity, either of genetic origin or environmentally/oxidatively
induced, is likely to contribute to the onset and progression of neurodegenerative disorders [23], making
this ﬁeld a timely and exciting research topic in neuropathological studies. Concerning ALS, additional
studies are required to elucidate the molecular mechanisms leading to impaired DNA repair activity in
motor neurons.
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